{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T16:03:59Z","timestamp":1767888239878,"version":"3.49.0"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,6]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Dried blood spot (DBS) sampling offers a minimally invasive sampling method for therapeutic drug monitoring of antipsychotics. To facilitate implementation in clinical practice, the aim of this study was to perform a clinical validation study of a DBS method for quantification of risperidone, aripiprazole, pipamperone, and their major metabolites 9-OH risperidone and dehydro-aripiprazole in a real-life, clinical setting.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Paired DBS and venous plasma samples were analyzed (n = 35 for risperidone, n = 21 for aripiprazole, n = 21 for pipamperone). Estimated plasma concentrations were calculated from DBS concentrations based on hematocrit and\/or Deming regression formulas. Deming regression and Bland\u2013Altman analyses were used to determine the agreement between the calculated and measured plasma concentrations. For Bland\u2013Altman analysis, the following acceptance limit was used: for a minimum of 67% of the samples, the difference of the 2 measurements should be within 20% of their mean.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>The median venous plasma levels were 0.9 mcg\/L for risperidone, 14.8 mcg\/L for 9-OH risperidone, 135.4 mcg\/L for aripiprazole, 54.9 mcg\/L for dehydro-aripiprazole, and 56.4 mcg\/L for pipamperone. All antipsychotics required different correction formulas of DBS concentrations for best agreement. Subsequently, no constant or proportional bias was observed using Deming regression analysis. With Bland\u2013Altman analyses, for risperidone, 45% of the samples were within the 20% limits; for 9-OH risperidone, 36%; for aripiprazole, 45%; for dehydro-aripiprazole, 35%; and for pipamperone, 43%.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>The DBS method to quantify risperidone, aripiprazole, pipamperone, and their major metabolites did not meet the acceptance criteria in the Bland\u2013Altman analyses. Therefore, this DBS method was not clinically valid. This study shows the importance of a clinical validation study with use of Bland\u2013Altman plots before clinical implementation.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000000502","type":"journal-article","created":{"date-parts":[[2018,3,4]],"date-time":"2018-03-04T20:16:34Z","timestamp":1520194594000},"page":"344-350","source":"Crossref","is-referenced-by-count":37,"title":["Dried Blood Spot Analysis for Therapeutic Drug Monitoring of Antipsychotics: Drawbacks of Its Clinical Application"],"prefix":"10.1097","volume":"40","author":[{"given":"Sanne M.","family":"Kloosterboer","sequence":"first","affiliation":[{"name":"Department of Hospital Pharmacy, Erasmus MC, Rotterdam, the Netherlands;"},{"name":"Department of Intellectual Disability Medicine Middin, The Hague, the Netherlands; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brenda C. M.","family":"de Winter","sequence":"additional","affiliation":[{"name":"Department of Hospital Pharmacy, Erasmus MC, Rotterdam, the Netherlands;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soma","family":"Bahmany","sequence":"additional","affiliation":[{"name":"Department of Hospital Pharmacy, Erasmus MC, Rotterdam, the Netherlands;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda","family":"Al-Hassany","sequence":"additional","affiliation":[{"name":"Department of Hospital Pharmacy, Erasmus MC, Rotterdam, the Netherlands;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annet","family":"Dekker","sequence":"additional","affiliation":[{"name":"Department of Intellectual Disability Medicine Middin, The Hague, the Netherlands; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gwen C.","family":"Dieleman","sequence":"additional","affiliation":[{"name":"Department of Child and Adolescent Psychiatry\/Psychology, Erasmus MC, Rotterdam, the Netherlands."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teun","family":"van Gelder","sequence":"additional","affiliation":[{"name":"Department of Hospital Pharmacy, Erasmus MC, Rotterdam, the Netherlands;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bram","family":"Dierckx","sequence":"additional","affiliation":[{"name":"Department of Child and Adolescent Psychiatry\/Psychology, Erasmus MC, Rotterdam, the Netherlands."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Birgit C. P.","family":"Koch","sequence":"additional","affiliation":[{"name":"Department of Hospital Pharmacy, Erasmus MC, Rotterdam, the Netherlands;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230814","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.euroneuro.2017.07.001","article-title":"International trends in antipsychotic use: a study in 16 countries, 2005\u20132014","volume":"27","author":"Halfdanarson","year":"2017","journal-title":"Eur Neuropsychopharmacol."},{"key":"R2-20230814","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1600-0447.2009.01425.x","article-title":"Antipsychotic prescribing trends: a review of pharmaco-epidemiological studies","volume":"121","author":"Verdoux","year":"2010","journal-title":"Acta Psychiatr Scand."},{"key":"R3-20230814","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)61764-X","article-title":"Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis","volume":"373","author":"Leucht","year":"2009","journal-title":"Lancet."},{"key":"R4-20230814","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1093\/aje\/kwf145","article-title":"Metabolic syndrome and development of diabetes mellitus: application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study","volume":"156","author":"Laaksonen","year":"2002","journal-title":"Am J Epidemiol."},{"key":"R5-20230814","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1055\/s-0043-116492","article-title":"Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017","volume":"51","author":"Hiemke","year":"2018","journal-title":"Pharmacopsychiatry."},{"key":"R6-20230814","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1007\/s002130000576","article-title":"Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia","volume":"153","author":"Spina","year":"2001","journal-title":"Psychopharmacology (Berl)."},{"key":"R7-20230814","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1177\/0269881107077357","article-title":"Serum prolactin levels, plasma risperidone levels, polymorphism of cytochrome P450 2D6 and clinical response in patients with schizophrenia","volume":"21","author":"Wang","year":"2007","journal-title":"J Psychopharmacol."},{"key":"R8-20230814","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1080\/15622970701361255","article-title":"Serum levels of aripiprazole and dehydroaripiprazole, clinical response and side effects","volume":"9","author":"Kirschbaum","year":"2008","journal-title":"World J Biol Psychiatry."},{"key":"R9-20230814","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.cca.2014.12.008","article-title":"Advances in detection of antipsychotics in biological matrices","volume":"441","author":"Patteet","year":"2015","journal-title":"Clin Chim Acta."},{"key":"R10-20230814","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.4155\/bio.15.100","article-title":"Are capillary DBS applicable for therapeutic drug monitoring of common antipsychotics? A proof of concept","volume":"7","author":"Patteet","year":"2015","journal-title":"Bioanalysis."},{"key":"R11-20230814","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.euroneuro.2017.01.009","article-title":"Dried Blood Spot sampling in psychiatry: perspectives for improving therapeutic drug monitoring","volume":"27","author":"Martial","year":"2017","journal-title":"Eur Neuropsychopharmacol."},{"key":"R12-20230814","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1097\/FTD.0000000000000411","article-title":"Dried blood spots combined with ultra-high-performance liquid chromatography-mass spectrometry for the quantification of the antipsychotics risperidone, aripiprazole, pipamperone, and their major metabolites","volume":"39","author":"Tron","year":"2017","journal-title":"Ther Drug Monit."},{"key":"R13-20230814","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ajhb.22463","article-title":"Development and validation of assay protocols for use with dried blood spot samples","volume":"26","author":"McDade","year":"2014","journal-title":"Am J Hum Biol."},{"key":"R14-20230814","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jpba.2016.06.026","article-title":"Clinical feasibility of dried blood spots: analytics, validation, and applications","volume":"130","author":"Enderle","year":"2016","journal-title":"J Pharm Biomed Anal."},{"key":"R15-20230814","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1002\/bmc.3610","article-title":"Identification and quantification of the antipsychotics risperidone, aripiprazole, pipamperone and their major metabolites in plasma using ultra-high performance liquid chromatography-mass spectrometry","volume":"30","author":"Wijma","year":"2016","journal-title":"Biomed Chromatogr."},{"key":"R16-20230814","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/bmc.1367","article-title":"Dried blood spot sampling in combination with LC-MS\/MS for quantitative analysis of small molecules","volume":"24","author":"Li","year":"2010","journal-title":"Biomed Chromatogr."},{"key":"R18-20230814","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1016\/j.chroma.2011.01.071","article-title":"Rapid assays of clozapine and its metabolites in dried blood spots by liquid chromatography and microextraction by packed sorbent procedure","volume":"1218","author":"Saracino","year":"2011","journal-title":"J Chromatogr A."},{"key":"R19-20230814","doi-asserted-by":"crossref","first-page":"892","DOI":"10.4088\/JCP.v63n1007","article-title":"Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature","volume":"63","author":"Lacro","year":"2002","journal-title":"J Clin Psychiatry."},{"key":"R21-20230814","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1002\/jcph.558","article-title":"Dried blood spot analysis for therapeutic drug monitoring of pazopanib","volume":"55","author":"de Wit","year":"2015","journal-title":"J Clin Pharmacol."},{"key":"R22-20230814","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s12907-015-0013-5","article-title":"The use of dried blood spot sampling for the measurement of HbA1c: a cross-sectional study","volume":"15","author":"Mastronardi","year":"2015","journal-title":"BMC Clin Pathol."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00007691-201806000-00009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T22:07:21Z","timestamp":1692050841000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007691-201806000-00009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000502","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]}}}